At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 763 enrolled
Drug / intervention
tapinarof cream, 1%drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Long-Term, Open-Label, Extension Study to Evaluate the Safety and Efficacy of Tapinarof Cream, 1% for the Treatment of Plaque Psoriasis in Adults
In Brief
A Phase 3 clinical trial evaluating tapinarof cream, 1% for Plaque Psoriasis. Completed, enrolled 763 participants across 104 sites in 2 countries.
Detailed Summary
This is a long-term, open-label, multicenter, study to evaluate the safety and efficacy of topical tapinarof cream, 1% in adults with plaque psoriasis. Subjects in this study completed treatment in 1 of 2 Phase 3 pivotal efficacy and safety studies (Study DMVT-505-3001 or Study DMVT-505-3002). This study will consist of up to 40 weeks of treatment and a 4-week safety follow-up period.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPlaque Psoriasis
CountriesCanada, United States
CollaboratorsIQVIA Biotech
Timeline
Phase 3CompletedFinished
2020202120222023202420252026
First PostedAug 2019
Enrollment StartAug 2019
Primary CompletionApr 2021
TodayJul 2026
First PostedAug 12, 2019
Enrollment StartAug 13, 2019
Primary CompletionApr 6, 2021
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 6.9 years ago
Interventions
tapinarof cream, 1%drug
Intermittent use of Tapinarof cream, 1%, applied once daily according to PGA score